Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new brain scan tracer aims to light up myelin damage

NCT ID NCT06999434

Diagnosis Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Researchers at Yale University are testing a PET imaging tracer called [18F]3F4AP to see whether it can measure demyelination, the loss of the protective myelin sheath around nerve fibers. The study includes healthy volunteers and people with conditions such as multiple sclerosis, spinal cord injury, mild cognitive impairment, and Alzheimer's disease. Participants receive PET scans with [18F]3F4AP and two other tracers that measure tau and amyloid proteins, and researchers compare the images with MRI scans to look for links between myelin damage and other brain changes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a PET imaging tracer called [18F]3F4AP
What this could lead to
If it works, this tracer could give doctors a way to see myelin damage directly in the brain and spinal cord, which may help diagnose and track conditions like multiple sclerosis and Alzheimer's disease.
What could go wrong
This is an early-phase imaging study with a small number of participants, so the tracer may not bind well enough to be useful, and PET scans involve radiation exposure that limits who can take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: 1. Male and Female subjects must be ≥18 and \<90 years of age; 2. Able to understand and provide informed consent prior to study procedures 3. Must be in good health Exclusion: 1. Less than 18 years of age; 2. Pregnant or breastfeeding; 3. Any significant systemic illness or unstable medical condition; 4. Pre-existing medical conditions or claustrophobic reactions; 5. Research-related radiation exposure exceeds current PET Center guidelines (i.e. 50 mSv in the prior 12 months); 6. History of a bleeding disorder or are currently taking anticoagulants.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alzheimer's disease(AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease demyelinating disease multiple sclerosis myeloid sarcoma radiculopathy spinal cord injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alzheimer's disease(AD) Demyelinating disorders MCI MS (multiple sclerosis) Sci - spinal cord injury Spinal radiculopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yale University PET Center

    RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.